BioDelivery Sciences International, Inc. (BDSI)
(Delayed Data from NSDQ)
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Should Value Investors Pick BioDelivery (BDSI) Stock Now?
by Zacks Equity Research
Let's see if BioDelivery (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.
BioDelivery (BDSI) Stock Up on Raised Guidance for 2021
by Zacks Equity Research
BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.
Why Is BioDelivery (BDSI) Down 20.8% Since Last Earnings Report?
by Zacks Equity Research
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioDelivery Sciences International (BDSI) Tops Q3 Earnings Estimates
by Zacks Equity Research
BioDelivery (BDSI) delivered earnings and revenue surprises of 16.67% and -2.28%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.
Analysts Estimate BioDelivery Sciences International (BDSI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioDelivery Sciences International (BDSI) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioDelivery (BDSI) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioDelivery Sciences International (BDSI) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioDelivery Sciences International (BDSI) Beats Q2 Earnings Estimates
by Zacks Equity Research
BioDelivery (BDSI) delivered earnings and revenue surprises of 80.00% and -1.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
BioDelivery Sciences International (BDSI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioDelivery Sciences International (BDSI) Misses Q1 Earnings Estimates
by Zacks Equity Research
BioDelivery (BDSI) delivered earnings and revenue surprises of -28.57% and 0.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioDelivery (BDSI) Down 12.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: BioDelivery Sciences (BDSI)
by Zacks Equity Research
BioDelivery Sciences (BDSI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. The company expects total revenues to be in the range of $170 - $180 million in 2021.
Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline
by Zacks Equity Research
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioDelivery (BDSI) Up 9.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is a BioDelivery Sciences (BDSI) Good Value Investor Stock?
by Zacks Equity Research
Let's see if BioDelivery Sciences International (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.
BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioDelivery (BDSI) Down 15.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioDelivery (BDSI) Q2 Earnings Miss, Revenues Beat, Stock Up
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. Stock up.
BioDelivery Sciences International (BDSI) Q2 Earnings Lag Estimates
by Zacks Equity Research
BioDelivery (BDSI) delivered earnings and revenue surprises of -75.00% and 0.87%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: BioDelivery Sciences International (BDSI) Q2 Earnings Expected to Decline
by Zacks Equity Research
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Bargain Hunting? Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.